KBC ANCORA 92.300 € (-0,97 %) RETAIL ESTATES 62.600 € (-1,73 %) UMICORE 16.630 € (+2,97 %) COLRUYT 36.940 € (-0,38 %) KBC 111.800 € (-1,15 %) KINEPOLIS GROUP 49.500 € (-2,17 %) D'IETEREN GROUP 173.000 € (-0,75 %) HYLORIS 4.300 € (+1,18 %) MELEXIS 55.400 € (+0,18 %) ELIA GROUP 127.200 € (-1,93 %) SHURGARD 24.450 € (-1,61 %) NYXOAH 0.799 € (+1,27 %) AEDIFICA 63.700 € (-2,38 %) CMB.TECH 14.880 € (-3,00 %) HOME INVEST BE. 18.280 € (+0,44 %) RECTICEL 12.340 € (-1,28 %) TUBIZE-FIN 230.600 € (-1,20 %) CELYAD ONCOLOGY 0.161 € (-8,00 %) SYENSQO 76.600 € (-1,73 %) VASTNED 26.850 € (-1,10 %) GBL 78.950 € (-0,94 %) ATENOR 0.860 € (-2,27 %) GIMV 48.400 € (-0,41 %) LOTUS BAKERIES 13 720.000 € (-0,72 %) IMMOBEL 17.600 € (+3,53 %) CARE PROPERTY INV. 12.680 € (-0,63 %) PROXIMUS 6.240 € (-1,58 %) TITAN S.A. 44.140 € (-0,05 %) JENSEN-GROUP 73.200 € (-1,35 %) CAMPINE 159.000 € (-3,34 %) AGEAS 76.250 € (-0,85 %) EVS 15.140 € (-2,57 %) CIE BOIS SAUVAGE 271.000 € (-1,81 %) ASCENCIO 52.700 € (-0,75 %) ACKERMANS V.HAAREN 267.000 € (-0,74 %) SOLVAY 24.120 € (-2,58 %) ORANGE BELGIUM 22.200 € (0,00 %) WDP 19.000 € (-2,11 %) ECONOCOM GROUP 1.490 € (-0,67 %) AGFA-GEVAERT 0.317 € (-1,71 %) SOLVAC 83.500 € (+0,60 %) EKOPAK 2.935 € (+1,21 %) SIPEF 108.600 € (0,00 %) DEME GROUP 158.200 € (-1,25 %) SOFINA 268.000 € (+0,07 %) BARCO 5.915 € (-1,09 %) XIOR 24.500 € (-1,80 %) AB INBEV 72.840 € (-2,93 %) ONWARD MEDICAL 1.454 € (-4,09 %) BEKAERT 40.650 € (-1,22 %) MONTEA 68.300 € (-1,73 %) ONTEX GROUP 1.204 € (+2,91 %) UCB 283.200 € (-0,67 %) BREDERODE 94.000 € (-0,11 %) IBA 16.320 € (-1,21 %) TINC 10.580 € (-1,31 %) AZELIS GROUP 11.840 € (-0,34 %) WERELDHAVE BELGIUM 51.000 € (0,00 %) ENERGYVISION 18.120 € (-1,84 %) VIOHALCO 16.100 € (+1,26 %)
AIR LIQUIDE 189.140 € (-0,32 %)
ASM INTERNATIONAL 689.200 € (+2,87 %)
PROSUS 32.095 € (-1,32 %)
LINEDATA SERVICES 48.000 € (+1,05 %)
FUGRO 7.880 € (-2,54 %)
OCI 4.240 € (+1,92 %)
LIGHTON 1.928 € (+24,39 %)
BOLLORE 3.610 € (+0,06 %)
LHYFE 1.490 € (-0,67 %)
WORLDLINE 9.550 € (-7,28 %)
WERELDHAVE 17.680 € (-1,12 %)
SAFRAN 301.100 € (-1,08 %)
KERING 179.320 € (+0,82 %)
INNELEC MULTIMEDIA 2.280 € (+8,57 %)
CROSSJECT 1.340 € (-0,30 %)
IPSOS 34.040 € (-1,73 %)
TKH GROUP 45.700 € (-0,39 %)
ICADE 14.350 € (-1,91 %)
SCHNEIDER ELECTRIC 235.250 € (-1,18 %)
SLIGRO FOOD GROUP 8.840 € (-2,32 %)
AXA 45.390 € (-0,72 %)
CREDIT AGRICOLE 15.465 € (-0,67 %)
TOTALENERGIES 79.160 € (-0,81 %)
ESSILORLUXOTTICA 176.800 € (-2,21 %)
ARCADIS 45.260 € (-2,29 %)
CARREFOUR 13.520 € (-1,60 %)
PLANISWARE 24.500 € (+1,03 %)
ABN AMRO BANK N.V. 40.100 € (-0,45 %)
ORANGE 15.035 € (-1,25 %)
KLEPIERRE 37.180 € (-0,91 %)
VERALLIA 16.940 € (-2,64 %)
TIKEHAU CAPITAL 15.900 € (-0,75 %)
ADYEN 806.400 € (-3,59 %)
PERNOD RICARD 70.940 € (-1,09 %)
ASML HOLDING 1 288.200 € (+2,17 %)
DANONE 67.780 € (-2,00 %)
WOLTERS KLUWER 86.320 € (+0,77 %)
CAPGEMINI 116.050 € (-2,68 %)
ACCOR 48.730 € (-3,12 %)
KUMULUS VAPE 2.820 € (0,00 %)
LARGO 0.800 € (0,00 %)
VIEL ET COMPAGNIE 19.180 € (-3,81 %)
BE SEMICONDUCTOR 151.200 € (+1,34 %)
AIRBUS 198.140 € (+0,18 %)
FERMENTALG 0.395 € (+1,02 %)
VALEO 10.895 € (-1,09 %)
CHRISTIAN DIOR 423.600 € (+0,71 %)
ENGIE 24.350 € (-1,22 %)
EXOR NV 71.600 € (-0,62 %)
DSM FIRMENICH AG 104.450 € (-0,29 %)
NEXANS 126.000 € (-1,87 %)
VINCI 112.100 € (-0,75 %)
AEGON 7.646 € (-0,52 %)
ACOMO 22.950 € (-0,43 %)
QWAMPLIFY 1.460 € (-2,67 %)
LEGRAND 133.600 € (-1,40 %)
SANOFI 83.790 € (-2,85 %)
CSG 9.324 € (-0,99 %)
ALTAREA 69.800 € (-1,83 %)
ARCELORMITTAL SA 54.840 € (-0,33 %) News Réglementées
|
18/11/2026 18:38
Medios Approves New Share Buyback ProgramEQS-News: Medios AG / Key word(s): Share Buyback Medios Approves New Share Buyback Program
Thomas Meier, CEO of Medios AG: “With this share buyback, we are consistently implementing the capital allocation strategy we presented at our Capital Markets Day in late September 2026. This measure also underscores our confidence in the strength of our business model, our financial performance, and the sustainable growth potential of our strategy.” Share buyback program is part of the “Medios Next Level” strategy As part of the “Medios Next Level” strategy unveiled in September, the company is targeting consolidated revenue of approximately 3.1 billion euros and an adjusted EBITDA margin1 of approximately 5.5% for fiscal year 2031. Medios had also announced that it would use share buybacks as its preferred instrument for returning capital to its shareholders. The buyback that has now been approved underscores – in addition to the Group’s profitable growth – Medios’ commitment to creating sustainable value for its shareholders. The new share buyback program also fits into this context. The repurchased shares can be used flexibly within the scope of the authorization granted by the Annual Shareholders’ Meeting, for example, as “acquisition currency” in corporate acquisitions, for employee stock ownership plans, or for stock-based compensation plans. Following the successful first share buyback program in fiscal year 2025, Medios will shortly retire the treasury shares acquired under that program – which currently total 986,362 shares (3.9% of the share capital) – and reduce the share capital accordingly. This will permanently reduce the number of outstanding shares with the aim of strengthening the long-term value per share for the remaining shareholders. 1 To improve transparency regarding its financial results, Medios will switch from “EBITDA pre” to a newly defined “EBITDA adjusted” starting in fiscal year 2027. Going forward, adjustments will be limited to two clearly defined categories: M&A expenses and restructuring costs. About Medios AG Medios is a European pharmaceutical services group with two operating segments –Specialty Pharma Supply and Compounding – and operates in Germany, the Netherlands, Belgium, and Spain. Working closely with pharmacies, specialist medical practices, and pharmaceutical companies, Medios combines pharmaceutical expertise, manufacturing capabilities, and smart services to enable reliable and efficient access to innovative and individualized therapies. The focus is on patients with complex and chronic conditions, including cancer, autoimmune diseases, and neurological and metabolic disorders. Medios AG is Germany's first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index. www.medios.group Kontakt Katrin Neuffer Director Investor Relations & Communications Medios AG Heidestraße 9 | 10557 Berlin T +49 30 232 566 800 ir@medios.group www.medios.group 18.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
2437942 18.11.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière